| Literature DB >> 26713112 |
Chudi O Ndubaku1, James J Crawford1, Joy Drobnick1, Ignacio Aliagas1, David Campbell2, Ping Dong3, Laura M Dornan1, Sergio Duron2, Jennifer Epler1, Lewis Gazzard1, Christopher E Heise1, Klaus P Hoeflich1, Diana Jakubiak1, Hank La1, Wendy Lee1, Baiwei Lin1, Joseph P Lyssikatos1, Jasna Maksimoska4, Ronen Marmorstein4, Lesley J Murray1, Thomas O'Brien1, Angela Oh1, Sreemathy Ramaswamy1, Weiru Wang1, Xianrui Zhao1, Yu Zhong1, Elizabeth Blackwood1, Joachim Rudolph1.
Abstract
Signaling pathways intersecting with the p21-activated kinases (PAKs) play important roles in tumorigenesis and cancer progression. By recognizing that the limitations of FRAX1036 (1) were chiefly associated with the highly basic amine it contained, we devised a mitigation strategy to address several issues such as hERG activity. The 5-amino-1,3-dioxanyl moiety was identified as an effective means of reducing pK a and logP simultaneously. When positioned properly within the scaffold, this group conferred several benefits including potency, pharmacokinetics, and selectivity. Mouse xenograft PK/PD studies were carried out using an advanced compound, G-5555 (12), derived from this approach. These studies concluded that dose-dependent pathway modulation was achievable and paves the way for further in vivo investigations of PAK1 function in cancer and other diseases.Entities:
Keywords: Kinase inhibitor; hERG; oncology; pKa
Year: 2015 PMID: 26713112 PMCID: PMC4677365 DOI: 10.1021/acsmedchemlett.5b00398
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345